Question 8 of 20 Fundamentals Concept
What are the five antibody isotypes, and how do their functions differ?
Short answer
IgM, IgG, IgA, IgE and IgD share the same antigen-binding design but differ in their constant regions, which decide what they do. IgM comes first and fixes complement well, IgG dominates serum and crosses the placenta, IgA protects mucosa, IgE arms mast cells, and IgD marks mature naive B cells.
Why
The heavy chain constant region sets the isotype, and class switching changes it without changing the antigen specificity. Secreted IgM is usually a pentamer. Each binding site has low affinity, but ten together give high avidity, and IgM activates complement strongly.
It dominates the early response. IgG is about three quarters of serum antibody. It has four subclasses, opsonizes antigen for phagocytes through Fc gamma receptors, can fix complement, and is carried across the placenta.
IgA is mostly a monomer in serum but a dimer in secretions, bound to a J-chain and a secretory component. It neutralizes microbes at mucosal surfaces and is abundant in colostrum. IgE has the lowest serum level and shortest half-life, yet binds its receptor on mast cells and basophils so tightly that tiny amounts trigger allergy and fight parasitic worms.
IgD appears with IgM on mature naive B cells through alternative splicing. For drug developers this matters because a therapeutic antibody's isotype and subclass set its effector function and half-life. IgG4 and IgG2, for example, fix complement poorly compared with IgG1.
A strong answer covers
- Constant region defines isotype and function
- IgM pentamer with high avidity and complement activation
- IgG dominant in serum, four subclasses, crosses placenta
- Secretory IgA dimer at mucosa, IgE on mast cells
- Isotype choice shapes therapeutic antibody behavior
Common mistakes
- Thinking class switching changes the antigen the antibody recognizes
- Treating all IgG subclasses as functionally identical
- Assuming IgE is unimportant because its serum concentration is low
The interviewer might ask next
Why might a developer choose an IgG4 rather than an IgG1 backbone for a blocking antibody?